Mrs Joyce A Selland, LPN | |
1323 Bia Route 4, Ft. Thompson, SD 57339 | |
(605) 245-1618 | |
(605) 245-2277 |
Full Name | Mrs Joyce A Selland |
---|---|
Gender | Female |
Speciality | Licensed Practical Nurse |
Location | 1323 Bia Route 4, Ft. Thompson, South Dakota |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1306379896 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
164W00000X | Licensed Practical Nurse | SD-LPN P004198 (South Dakota) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Joyce A Selland, LPN Po Box 200, 1323 Bia Route 4, Ft. Thompson, SD 57339 Ph: (605) 245-1618 | Mrs Joyce A Selland, LPN 1323 Bia Route 4, Ft. Thompson, SD 57339 Ph: (605) 245-1618 |
News Archive
About 30% of breast cancer patients have tumours that show rapid growth and invasion through the body. A common denominator in all of these cases is the presence of a large number of Her2 proteins in tumour cellular membranes. Consequently, these aggressive tumours are referred to as HER2+. Scientists working in the Metastasis Laboratory (MetLab) at IRB Barcelona headed by ICREA researcher Roger Gomis, have described the molecular mechanism that induces HER2+ tumours to ignore the signals that protect cells from excessive growth.
"Data presented from the FEM-PrEP trial by Dr. Lut Van Damme Tuesday at the 19th Conference on Retroviruses and Opportunistic Infections in Seattle highlighted the challenge that adherence plays in successfully deploying effective Pre-Exposure Prophylaxis (PrEP) interventions," HIV Medicine Association Executive Director Andrea Weddle writes in this guest post in the Center for Global Health Policy's "Science Speaks" blog.
Biomedical researchers at the University of Arkansas in Fayetteville and the University of Arkansas for Medical Sciences (UAMS) in Little Rock have developed a special contrast-imaging agent made of gold-coated carbon nanotubes that is capable of molecular mapping of lymphatic endothelial cells and detecting cancer metastasis in sentinel lymph nodes.
Boston Scientific Corporation today announced that its PROMUS® Element™ Everolimus-Eluting Coronary Stent System has received CE Mark approval for use in patients with diabetes and those experiencing an acute myocardial infarction (AMI), or heart attack.
Critical Path Institute announced today that it will open access to the Duchenne Regulatory Science Consortium (D-RSC) database to qualified researchers, through its Rare Disease Cures Accelerator, Data and Analytics Platform.
› Verified 6 days ago
Mrs. Sheryl Denise Saxton, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: Hwy 34 And 47, Ft. Thompson, SD 57339 Phone: 605-245-2283 Fax: 605-245-2384 |